New agents directed against molecular targets have now been tested in large prospectively randomized clinical trials for patients with untreated advanced non-small cell lung cancer (NSCLC). The trials have included small molecule inhibitors of receptor tyrosine kinases (gefitinib and erlontinib), ...
It encapsulates the research on nanoparticles within this domain, elucidating their applications in early screening, diagnostics, conventional treatments, targeted therapies, and immunotherapies for lung cancer. By critically assessing the strengths and limitations of various nanomaterials, along with their ...
According to Kumar, because of the high need for newer therapies future considerations for multiple myeloma treatment are currently in development and are showing promise in clinical trials. One of these potential treatments is iberdomide (CC-220; Bristol Myers Squibb), and like lenalidomide (Revlim...
Interestingly, GSIs have been used in long-term treatments in Alzheimer´s patients without major side effects (although without improving the course of the disease). The accumulated knowledge on the pharmacology of GSIs should pave the way to test these compounds in NSCLC patients....
Emerging treatments for noise-induced hearing loss. Expert Opin. Emerg. Drugs 16, 235–245 (2011). Article CAS PubMed PubMed Central Google Scholar Humes, L. E. & Joellenbeck, L. Noise and Military Service: Implications for Hearing Loss and Tinnitus. (National Academies Press, 2005). ...
PCN114 ASSESSMENT OF THE SURVIVAL BENEFIT AND COST IMPACT OF NEW TREATMENTS FOR KEY ANSCLC BIOMARKERS USING THE ITEN MODELdoi:10.1016/j.jval.2019.09.311D. GrimaD. MoldaverM. HurryValue in Health
Emerging treatments for noise-induced hearing loss. Expert Opin. Emerg. Drugs 16, 235–245 (2011). Article CAS PubMed PubMed Central Google Scholar Humes, L. E. & Joellenbeck, L. Noise and Military Service: Implications for Hearing Loss and Tinnitus. (National Academies Press, 2005). ...
With newer agents approved for patients with chronic lymphocytic leukemia, physicians are now challenged with how best to utilize them.
MARIPOSA: Amivantamab, Lazertinib Shows Improvements in Survival End Points for NSCLC Pharmacy Students Embrace Collaborative, Interactive Learning Strategies Overcoming the Challenges of PBMs: Expanding Patient Access to Affordable Treatments Public Health Matters Video: The Difference Between Misinformation...
Several new effective treatments of lung cancer have emerged in the treatment of NSCLC, including targeted therapies, e.g., against genetic aberrations in EGFR, ALK, BRAF, KRAS, ROS1, RET, MET and NRTK genes [22]. ICI treatments, often in combination with chemotherapy, have also become ...